The spending package passed by Congress on Tuesday includes an effort to drive down drug prices, by imposing new restrictions on some of the most controversial practices of the giant companies that oversee prescription benefits.
The legislation represents a significant political defeat for the companies, known as pharmacy benefit managers or PBMs, which for years had largely escaped public attention, regulation and oversight. And it represents a win for drugmakers, which have long lobbied to deflect blame for high drug prices toward the PBMs.
In signing the overall package Tuesday afternoon, President Donald Trump singled out his efforts to reduce drug prices.
While the new restrictions on PBMs received widespread support, it is unclear how much they will benefit the government, employers and patients. There are complex reasons for high drug prices, and the legislation still preserves many core elements of the benefit managers’ opaque business model that contributes to high drug prices.
The three largest benefit managers — CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx — collectively oversee some 80% of all prescriptions in the United States. Employers and government programs hire PBMs to negotiate with drug companies, pay pharmacies and help decide which drugs patients can get at what price. Patients see the work of a benefit manager when they encounter denials for coverage of prescriptions or are forced to switch medications.
